ARlow or AR- PCa with neuroendocrine differentiation constitutes a form of aggressive AR-independent CRPC that occurs either de novo or through transdifferentiation, for which therapeutic approaches are limited to chemotherapy (5). The gene discussed is AR; the disease is posterior cortical atrophy.